Alector Inc (ALEC) - News Archive

Alector s Advancements and Challenges in Neurodegenerative Therapies: A Comprehensive Update SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 Alector, Inc. (Nasdaq: ALEC), a prominent clinical-stage biotechnology firm, contin...

Alector Inc. a biotech company specializing in immuno-neurology therapies, is at a pivotal moment as it reports its financial results for the fourth quarter and full year of 2024. With the anticipated topline data from...

: This article evaluates the recent Phase 2 clinical trial results released by Alector Inc. for their investigational drug AL002 targeting individuals with early Alzheimer s disease. Additionally, it provides a brief bu...

Alector Unveils Pivotal Insights at ISFTD 2024: Charting a Path for Latozinemab in FTD-GRNAt the recently concluded 14th International Conference on Frontotemporal Dementias (ISFTD 2024), Alector Inc. showcased compelli...

As the battle against Alzheimer’s disease (AD) intensifies, Alector Inc. is casting a hopeful light on its innovative approach to treatment with the presentation of baseline characteristics from the INVOKE-2 Phase 2 cli...

In a significant development for the field of Alzheimer s disease research, Alector recently announced the dosing of its first patient in the PROGRESS-AD Phase 2 clinical trial. Conducted in partnership with GSK, this i...

In a significant development in dementia therapy, the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Latozinemab for the treatment of Frontotemporal Dementia due to a Progranulin...

South San Francisco, Calif., Jan. 19, 2024 - In an impressive move for the field of immuno-neurology, Alector, Inc. (Nasdaq: ALEC), a leading clinical-stage biotechnology company, has successfully completed its underwri...

Alector Announces Pricing of Public Offering of Common StockSOUTH SAN FRANCISCO, Calif., Jan. 17, 2024 - Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company specializing in immuno-neurology, disclosed t...

SOUTH SAN FRANCISCO, Calif. - Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company leading the way in immuno-neurology research, disclosed its plan today to offer shares of its common stock to the public...